Boda Pharmaceutical

Boda Pharmaceutical, officially Jilin Boda Pharmaceutical Co., Ltd., is a prominent Chinese pharmaceutical company specializing in the development and manufacture of stroke management medications and generic drugs. Founded in 1952 and headquartered in Liaoyuan, Jilin, the company became a key subsidiary of Simcere Pharmaceutical Group following a series of acquisitions starting in 2007. Boda is best known for its neuroprotective agent, Edaravone (marketed as Yidashen), which holds a significant share of the Chinese market for acute ischemic stroke treatment. The company's portfolio also includes a wide range of branded generics in therapeutic areas such as cardiovascular health, infectious diseases, and gastrointestinal disorders. With multiple GMP-certified manufacturing sites, Boda Pharmaceutical serves as a critical production and R&D hub within the Simcere Group.